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1Protocols for TTO Valuations of Health States Worse than Dead –
A literature review and framework for systematic analysis
1. Introduction
Resource allocation decisions in the health care sector are under ever increasing levels
of scrutiny. Cost-Utility Analysis (CUA) is the most widely used method of
economic evaluation used to inform such decisions.  This involves estimating, for any
potential new treatment, the incremental cost per Quality Adjusted Life Year (QALY)
gained, in comparison with the existing treatment. QALYs are calculated by
multiplying the duration in any given health state by the corresponding values for the
health-related quality of life in each period. These values are anchored at 1 for ‘full
health’ and 0 for ‘dead or equivalent’; values < 0 represent states considered to be
‘worse than dead’ (SWD). The terms ‘utility’, ‘value’ and ‘preference’ are often used
interchangeably in the literature on CUA and QALYs – although the distinction
between the terms and underlying concepts continues to be a matter of academic
debate (for example, see Drummond et al. 2005, p.140-147, and Parkin and Devlin
2006).
There are three main methods for eliciting preferences to yield a value for the quality
adjustment in the QALY: time trade-off (TTO), visual analogue scale and standard
gamble. The TTO method, developed by Torrance et al (1972), is the focus of this
review, and consists of a trade-off between length and quality of life. Participants in
TTO exercises are presented with a choice between two scenarios. In the case of a
TTO valuation for a chronic state better than dead (SBD) one of these scenarios
consists of living for a given fixed period of time (tj) (e.g. 10 years) in the health state
to be valued, followed by death. The other scenario (the ‘trading scenario’) consists
of a shorter period of time (ti) in full health, followed by death. The value of ti is
varied in the trading scenario until a point of indifference between the two scenarios is
found and then (assuming zero temporal discounting) the utility value for that health
state is given by the value ti/tj. TTO exercises can be undertaken by medical experts,
2members of the general population or patients. Furthermore, people can be asked to
value either their own current health or health states which are hypothetical to them.
In the case of SWD, there are two commonly used TTO protocols, both of which
differ from the protocol for SBD. The method developed by Torrance (1982) gives
respondents a choice between a scenario of living in full health for ti years followed
by the state to be valued for tj years (ti + tj= T), followed by death; and an alternative
scenario which is to die immediately. The value T is fixed e.g. 10 years. The value of
ti (and therefore also the value of tj) is varied until a point of indifference is found
between the two scenarios. The utility value for that health state is then given by –ti/tj.
The protocol used in the Measurement and Valuation of Health (MVH) study (Dolan
1997), which generated the UK’s TTO value set for the EQ-5D (Brooks, 1996) used a
method similar to this, but the first scenario is to live in the health state to be valued
for tj years followed by full health for ti years (i.e. the ordering of the two states is
reversed). The second scenario is still to die immediately, and the formula used to
obtain the value of the state is the same as that used in the Torrance method. The
reversing of the states in the first scenario (the state to be valued then full health vs.
full health then the state to be valued) was based on the argument that this ordering of
states forced the respondent “to think more directly about being in that state for y
number of years and thus to recognise the sacrifice that must be made before being in
full health for x number of years” (Gudex 1994 p.3). One way in which the
participant may not consider the sacrifice appropriately in the Torrance approach is if
they think they can commit suicide once they have enjoyed the time in full health and
before the state to be valued begins. If participants do take such a view then their
responses would be meaningless.
However, the MVH protocol, although widely used and replicated in subsequent
studies, is by no means a perfect alternative to the Torrance method. For example,
some respondents may not consider the scenario of going from a very poor health
state to full health to be realistic (some extremely poor states may be most realistically
associated with terminal illnesses; see for example Robinson et al, 1997). This is
problematic if participants are not fully engaging with the task and hence not
providing values that are a meaningful representation of their preferences. Unrealistic
3scenarios can also be problematic if participants refuse to respond to the questions,
although this may be considered preferable to a meaningless and inaccurate response.
The ordering of full health to poor health (as in Torrance) or poor health to full health
(in the MVH) may also be important where additive separability (Broome, 1993) does
not hold. That is, the same state may be valued differently depending on whether it is
part of a declining health profile (i.e. followed by death) or part of an improving
health profile (i.e. followed by full health). If so, one may argue that where SBD are
followed by dead so should SWD (as is the case in the Torrance design).
There are a number of other important problems associated with both the Torrance
and MVH approaches to TTO valuation of SWD. In both cases, valuations for SBD
are elicited using fundamentally different trade-off procedures to those used for SWD.
This implies that the aggregation of participants’ results for a given state across SBD
and SWD (e.g. in order to calculate means or in the estimation of value sets) is of
questionable validity. Secondly, the denominator of the utility value calculation (T-ti)
is no longer a fixed number as it is in the protocol for SBD (tj). One consequence of
this is that the method is problematic if people have very different valuations for
health experienced for different periods of time. Another consequence is that negative
values can be extremely negative. A participant who would not accept any amount of
time, however short, in a poor state of health, is implying that such a state is infinitely
bad. Given the mathematical intractability of dealing with negative infinity (a single
value of negative infinity in a sample of respondents would give a mean value of
negative infinity) researchers usually censor such responses. Under such censoring the
lower bound is determined by the (relatively arbitrary) choice of units of time that are
used in the study. For example, the lowest value that the MVH study elicited was -39,
which was a result of performing the TTO in units of 3 months.  If respondents stated
that 9 years and 9 months in full health, followed by 3 months in the severe state, was
equivalent to death their value would be given by, - 9.75/0.25 = -39. If the protocol
had instead restricted trades to whole years, the minimum value would have been: -
9/1= -9. Alternatively, if participants had been allowed to trade in months, the
minimum value would have been: -9.92/0.08= -119. A third problem is a direct
consequence of these extreme negative values. The conventional use of QALYs in
CUA views an improvement from -0.2 to 0 as identical to an improvement from 0 to
40.2. However, if the negative values do not fit the range 0 to -1, some individuals
may have a disproportional influence upon the calculation of means and tariffs. One
established response of researchers has been to transform negative values to fit the
scale 0 to -1 (Torrance et al. 1982; Patrick et al 1994). Lamers (2007) reports and
compares three methods of achieving this transformation: monotonic (as used in the
MVH study), linear and truncation.
However, it is not obvious why there should be no states worse than -1. While it
makes data analysis easier to transform values in this fashion, arguably one year of
extreme pain and discomfort might provide as much disutility as two years of full
health provides in utility. Richardson and Hawthorne (2001) do not share this view
and argue, based on the results from a VAS survey and their belief that it is not
possible for individuals to experience a state as bad as -1, for an even higher lower
limit of -0.25. Patrick et al (1994) point out that, once transformed, the negative
numbers for SWD can no longer be interpreted as “utility scores”, measured on the
same scale as those for SBD. However, if positive and negative values are not
measured on the same scale then comparison and aggregation becomes problematic.
An additional problem associated with the use of different TTO valuation procedures
for SBD and SWD is the existence of a ‘gap effect’ in the MVH TTO values around
dead, as observed by Stalmeier et al. (2005). In an analysis of differences in the
values for adjacent states, they find the differences in TTO values for states either just
above or below 0 are at least twice as large compared to the differences between other
adjacent states. Further, while there are a large number of states valued at exactly 0 in
the MVH TTO value set, there are relatively few states that are close to 0 (> 0 or < 0).
This means that SWD tend to be substantially worse than dead. While this may reflect
the genuine preference of the participants in TTO exercises, on the other hand, it may
be caused by the separate valuation procedure employed for SWD. It may also be
partially related to a further problem with the MVH protocol: when a SWD is
encountered, participants are explicitly asked whether a state is worse than dead early
on in the valuation process, by making a choice between immediate death and 10
years in the health state to be valued.  This may result in a ‘focusing effect’: by asking
participants to consider a stark trade-off between life in a given poor state of health
5and death, this may result in an exaggeration of their expressed dislike of the state. A
uniform procedure for SWD and SBD could avoid this potential problem.
The above problems with existing protocols for SWD have potentially important
implications for the conduct of CUA. The aim of this review is to provide an in-depth
account of the different ways of presenting the TTO for SWD, in order to identify any
alternatives to the MVH and Torrance approaches, and to consider the relative merits
of the approaches identified. This is achieved firstly by examining all health state
valuation studies that have employed the TTO, to record, categorise and report the
way that SWD are (or are not) handled. Secondly, in order to ensure that there are no
unpublished but potentially feasible TTO variants we set out a framework for
identifying all potential variants and assess the feasibility of each. While there have
been two recent reviews of TTO methodologies (Arnesen and Trommald, 2004;
Arnesen and Trommald 2005), the focus of these reviews are on different issues – for
example, the latter aimed to identify instances in which the TTO method had been
used to value own (current) health in order to see if QALY values from different TTO
studies are comparable. In contrast, the present review has its emphasis on
identifying different valuation procedures for SWD.
2. Methods and results of the Literature Search
Studies were retrieved from a literature search in the database Medline (via Ovid),
from 1950 to September 2007. The search was of titles and abstracts. The initial
search term was ‘TTO or Time Trade Off’, yielding 493 results. These results were
cross-referenced against the most recent systematic review of TTO methodologies by
Arnesen and Trommald (2005; henceforth A&T). Cross referencing showed that five
studies identified by A&T did not appear in our search results. A&T do not provide
fine detail of their search terms and simply state, “The search criterion was ‘Time
trade-off,’ in different spellings” (p.40). Including the search term ‘Time Tradeoff’
gave an additional 98 results but cross referencing showed that 1 study was still
missing. Finally, including the term ‘Time Tradeoffs’ gave a further 2 results, 1 of
which was the elusive article in A&T.  This brought the total number of results to 593.
Since the chosen method was a title and abstract search, we do not claim to have
6identified all existing studies that employ TTO elicitation of values - it is possible that
some studies may do so but not explicitly mention this in either the title or the abstract.
When searching for and reviewing studies, no distinction was made between the terms
mentioned earlier – ‘utility’, ‘value’ and ‘preference’.
The above process highlights the importance of attention to detail in the terminology
used in this area. There is a need for awareness of potential pitfalls when conducting
literature searches of this nature and also to encourage uniformity in terminology in
future studies. In this vein, it is worth noting that the use of hyphens within all Ovid
databases makes no difference to the results obtained. However, within other
databases the user may need to specify any hyphens to be included in the search terms.
Any study that had administered a TTO first hand was included, and logged in an
Excel spreadsheet. Some studies could be excluded on the basis of the title, some
could be excluded on the basis of the abstract and in some cases it was necessary to
read the article. Commonly excluded articles were studies on ‘tea tree oil’, reviews
(e.g. Torrance, 2006), theoretical comparisons of utility measurement techniques (e.g.
Rittenhouse, 1997) and comments on other studies (e.g. Hawthorne et al. 2003).
Theoretical discussions of TTO were only included if they specifically focused on
valuation of SWD (e.g. Richardson et al. 2001), and were used to assess possible
frameworks for TTO but were not included in the review of empirical data. For the
studies included in the review (see Appendix), the variables used to record and
categorise these are provided in Table 1.
As well as the articles identified through the database search, a number of articles
were included that the authors had prior knowledge of and which would not appear in
a database search owing to their source. These included papers from the Health
Economists’ Study Group archive, University of Monash Centre for Health
Economics Working Papers, and an unpublished manuscript.
7Table 1. The data extraction form
Variable Options
First Author
Year of publication
Journal Name
Title of Article
Valuing own health or hypothetical health state? Own, Hypothetical, Both
Is the wording of the TTO given? No, Partly, Yes
Is there a protocol for SWD? Separate from SBD, same as SBD, no, NA, unclear
If yes, then which protocol? MVH, Torrance, Modified MVH, Other
Time horizon (T) for SWD? 10 years, 20 years, Unclear, NA
Smallest unit of TTO?
1 hour, 1 day, 0.5 weeks, 1 month, 2 months, 3 months, 6
months, 1 year, unclear
Mode of administration?
Interview, internet questionnaire, postal questionnaire, self-
completed computer questionnaire, self-completed paper
questionnaire, telephone, interview, other
Are props used? Yes, No, With and without, Unclear,
Was the study part of the valuation of an existing
health state classification instrument? Yes/No
If yes, then which instrument?
Are the SWD values transformed? Yes, No, Unclear, NA
If yes, what is the range? -1 to 0, -0.25 to 0
83. Results of the Review
A total of 369 articles were included in the review1.  Table 2 shows the distribution of
the key variables.
Table 2. Distribution of key variables (n=369)
Frequency Percent
Hypothetical State only 121 32.8%
Own State only 199 53.9%
Both 49 13.3%
Wording of TTO given 75 20.3%
Wording not given 246 66.7%
Wording partly given 48 13.0%
Protocol for SWD separate from SBD 27 7.3%
Protocol for SWD same as for SBD 2 0.5%
All states assumed better than dead 333 90.3%
Unclear or NA 7 1.9%
Interview 282 76.4%
Self-completed computer questionnaire 25 6.8%
Self-completed paper questionnaire 24 6.5%
Telephone Interview 12 3.3%
Postal questionnaire 13 3.5%
Other or Unclear 13 3.5%
Use Props 127 34.4%
Don't use Props 68 18.4%
With and Without 2 0.5%
Unclear 172 46.7%
The majority of TTO valuation studies asked respondents to value their own health
(53.9%), largely accounted for by studies within clinical trials. Only 32.8% of the
studies asked respondents to value hypothetical health states. There is also a large
number of studies that include TTO valuation tasks on both hypothetical health states
and own health. These can predominantly be accounted for by studies that compare
patient and population values for a specific condition (e.g. arthritis - see Souchek et al.
2005), and studies (often clinical trials) that obtain health state valuations from both
1 We were unable to access 8 articles.  The abstracts suggest that although time trade-offs may have
been administered they were likely to be valuing own health in clinical trials and hence are highly
unlikely to be of importance in identifying protocols for SWD.
9patients and clinical experts (e.g. Wells, et al. 2004). Of the 369 studies, 11 valued an
existing health state classification instrument. Eight of these were generating EQ-5D
value sets in different countries. The other three consisted of two condition specific
measures and a valuation of the Assessment of Quality of Life (AQoL) Instrument
(Richardson et al 2004). All but the two condition specific measures included a
protocol for states worse than dead (MVH in all cases).
If a study included the wording of the TTO elicitation procedure in quotation marks
within the text, in a separate box (as seems to be the most common and clearest
method of reporting), or even if a thorough explanation had been given in the text,
then we deemed that the wording of the TTO had been given. If a less detailed and
more general explanation was given we deemed that the wording had been partly
given. Despite these rather generous criteria, 66.7% of the studies fell into the
category of ‘wording not given’. This is alarming given the extent to which health
state valuations can be affected by the framing of valuation exercises (see for example
Nord, 1992), and the widely acknowledged need for transparency in the reporting of
economic evaluations and clinical studies.  The poorest reporting seems to be amongst
medical studies (clinical trials and RCTs) which attached less importance to all
aspects of the methods section.
A further indication of poor reporting is in the case of the use of props and visual aids.
In 46.7% of studies it was unclear whether or not props had been used. Among the
studies in which it was possible to determine whether or not props had been used,
more studies (34.4%) used props than did not (18.4%). It is important to know
whether props have been used as they are likely to affect the way participants respond
to the valuation task. Therefore, if researchers wanted to replicate the study using a
different sample and compare results they would need to know whether or not props
had been used, and if so, what kind. Ideally, studies that do not use any props should
explicitly report that none were used.
The majority of studies used interviews to administer the TTO exercise (76.4%).  The
second most common method was self-completed computer questionnaire (6.8%),
predominantly through the software U-Titer (Summer et al. 1991). Self-completed
paper questionnaire was equally prevalent (6.5%). The ‘other’ category included two
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internet based questionnaires and five group sessions. The internet and computer
based modes of administration were used in more recent studies: the earliest internet
based questionnaire was published in 2001 (Chang et al. 2001) and the earliest
computer based questionnaire was published in 1995 (Nease et al. 1995).
The review only identified 29 studies – just 7.9% of those in our review – that had
allowed for the possibility that a state to be valued by participants might be
considered to have a value less than zero, and the characteristics of these studies can
be found in Table 3. Twenty seven of these protocols employed a TTO procedure for
SWD that was different to the protocol for SBD, of which 23 used the MVH protocol
and 4 used the Torrance protocol.
Table 3. Distribution of key variables for studies employing a protocol for states
worse than dead (n=29)
Frequency Percent
Hypothetical State only 27 93.1%
Own State only 2 6.9%
Both 0 0.0%
Wording of TTO given 5 17.3%
Wording not given 17 58.6%
Wording partly given 7 24.1%
Interview 27 93.2%
Self-complete computer questionnaire 1 3.4%
Group Session 1 3.4%
Use Props 21 72.4%
Don't use Props 0 0.0%
With and Without 1 3.5%
Unclear 7 24.1%
Smallest unit of TTO - 1 year 12 41.4%
1 day 3 10.3%
6 months 2 6.9%
Other 2 6.9%
Unclear 10 34.5%
SWD values transformed 19 65.5%
SWD values untransformed 9 31.0%
Unclear 1 3.5%
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A notable exception of the 29 is the study by Robinson and Spencer (2006), which
reported a TTO procedure that was the same for SWD and SBD. This study imitated
a TTO by asking respondents to rank different life profiles consisting of combinations
of good health, poor health and death. The principal innovation of the method is its
introduction of a ‘lead time’ in full health in each of the alternatives presented. The
approach avoids the need to have different valuation procedures for SBD and SWD
by allowing participants to trade their lead time to avoid the poor health state.
The other study that used the same protocol for SWD and SBD, by Detsky et al.
(1986), used a two stage TTO procedure with chaining. Respondents first valued
state 1 (SBD) in the normal TTO fashion.  They were then asked to choose between
one month in health state 1 and one month comprising a number of days in health
state 2 (potentially worse than dead) and the remainder in full health.  The number of
days in full health is varied until the respondent is indifferent between the two
options.  The point at which indifference is achieved is chained via the previously
obtained value for health state 1 to produce a value for health state 2, which can
potentially be worse than dead.  This approach has several disadvantages. Firstly, it is
time consuming and complex and does not enable researchers to calculate a value for
a SWD unless a SBD has already been valued. Secondly, the second stage of the
TTO implies variable denominators when calculating the value, and as a result, values
for SWD may be 'extremely' negative, as in the Torrance or MVH designs. However,
the paper does not discuss whether there were observations less than -1, and if there
were, what was done about them. As a result, whilst this approach uses a unified
protocol for SWD and SBD, it does not solve the key problems of the current
protocols for SWD. A citation search of Detsky et al. (1996) suggests that there are
no publications that used this approach since.
A further study, by Stalmeier et al (2007), is not a TTO (and hence not included in the
tables above, or considered in the following section on possible TTO variants) but is
arguably relevant in this context. The approach asks respondents to make a binary
choice between whether they think a health state is worse than dead. The responses
are only useful for health state values at the aggregate level. If state X is preferred to
dead (by an individual) it receives a score of 1, if state X is considered equal to dead it
receives a score of 0, and if state X is considered worse than dead it receives a score
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of -1. Scores can then be aggregated across respondents. For example, if 70%, 20%
and 10% of the respondents had respectively responded with ‘better than dead,’ ‘equal
to dead’ and ‘worse than dead’, then the health state would receive the following
value: (0.7×1) + (0.2×0) + (0.1×-1) = 0.6. This method is dependent upon the
existence of large variations in responses between individuals. For example, for a
state with a value in the MVH value set of 0.5 to gain the same value through the
Stalmeier method, half of the respondents would have to indicate that this state was
worse than dead, while the other half would have to indicate that it was better than
dead.
All but two of the studies using a protocol for SWD ask respondents about a
hypothetical health state – this is probably a product of the ethical considerations
involved in asking people to contemplate the possibility that their own health state
may be worse than dead. Furthermore, individuals who are likely to value their health
state as worse than dead are arguably less likely to be able to complete a TTO
exercise. The first of the two studies that used a protocol for SWD and valued own
health was by Konig, Roick and Angermeyer (2007) and elicited values for patients
with schizophrenic, schizotypal or delusional disorders. The negative values were
unbounded (and ranged from -1.9 to 0). The study is unclear about how many
respondents gave negative values but given that the mean TTO score is 0.75 one
would suspect only a few negative values were given. The authors acknowledge that
the reliability of TTO results elicited from patients with mental disorders is
questionable. The second study, by Detsky et al. (1986), asked respondents to value
the state of health they had experienced two months prior to the interview (generally a 
state of chronic malnutrition). The mean TTO score obtained was -0.30. The
standard deviation was very high (0.99) which may be a result of the two stage
procedure described earlier.
Given the complexity of using two different protocols, one for SBD and one for SWD,
this means participants are likely to require a substantial amount of explanation and
guidance.  This explains why none of these studies was administered via postal survey.
All but two of the 29 studies use the interview method of administration. The two
other studies used a group session which allows for explanation and guidance, and a
self-complete computer questionnaire which uses graphical props. As with the full
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sample of studies, the standards of reporting are poor. Of the 29 studies, 17 do not
give the wording of the TTO explicitly, and it is unclear in 7 of them whether props
have been used. An interesting observation is that the use of props appears to be more
prevalent amongst studies employing a protocol for SWD (72.4% compared with
34.3%). This is most probably due to the more complex nature of using multiple
procedures which necessitates the improved clarity introduced by using props.
The most common unit of TTO for SWD was 1 year which, given that 21 of the 29
studies had a time horizon of 10 years for SWD, means that these SWD values, if left
untransformed, would have a lower bound of -9. However, in 19 of the 29 studies the
SWD values were transformed. All but one of these transformations were to fit to the
range -1 to 0, with the other being to the range of -0.25 to 0 (Richardson et al. 2004,
as noted earlier).
4. Conclusions from the literature review
The most striking findings of our review of the published literature are as follows:
(i) TTO valuation research appears to be characterised by attempts to elicit values
from patients, rather than from members of the general public. Partly for this
reason,
(ii) A relatively small number of studies incorporate valuation procedures that
allow for states to be worse than dead in TTO.
(iii) All of those TTO studies that do address SWD, with two notable exceptions,
employ separate elicitation procedures for SWD than SBD.
(iv) Reporting standards regarding TTO valuation exercises are generally poor,
with widespread under-reporting of interview techniques, the nature of visual
aids and props and how they were used, and other key aspects of methods
known to affect the values.
Reporting of studies using TTO need to be improved and standardised. This stretches
from the specific term used for TTO in the title and abstract, to accurate and precise
descriptions of the TTO protocol used, whether props were included, what the
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smallest unit of trade-off was, and so on. The first point here is highlighted by the
problems encountered when trying to replicate the search terms used in the review by
A&T. Furthermore, the need to improve reporting standards for comparability across
studies is becoming recognised and for example within the U.K the National Institute
for Health and Clinical Excellence (NICE) has published guidelines for performing
and reporting economic evaluations submitted to the Institute (NICE, 2008)2.
The interview mode of administration is the most prevalent in TTO studies, especially
amongst studies with protocols for SWD. This is encouraging because the interview
approach is generally considered to be the most accurate and reliable, given that the
interviewer is able to ensure that the participant fully understands the exercise and can
also encourage the participant to give as much thought as possible to the key decisions.
However, the interview method is both time consuming and expensive. The internet
now provides an inexpensive and easy alternative that enables researchers to gain
large sample sizes. One emerging research topic in this context is the extent to which
face-to-face interview surveys and on-line surveys generate similar data.
The majority of studies identified in our review asked people to value their own health,
while amongst the smaller number of studies using protocols for SWD, the majority
ask people about health states which are hypothetical to them. Further comparison of
the two sets of studies shows that the use of props is more common amongst the latter.
Almost all the studies identified that had a protocol for SWD used either the Torrance
or MVH protocols, so are subject to the issues noted in our Introduction. Further, 19
of the 29 studies with protocols for SWD transformed the resulting negative values,
which is also problematic. This review reinforces the need for a protocol that is able
to elicit values for SBD and SWD in a ‘one size fits all’ fashion. If SWD are valued
in a uniform protocol with SBD then it is anticipated that there will be no need – or
justification – to transform, since the values for SWD will be on the same scale as the
values for SBD, and therefore will need to be taken at face value. Furthermore, a ‘one
size fits all’ protocol would produce consistent results irrespective of the choice of
2 A new set of NICE guidelines are currently under consideration and are likely to be confirmed and
published by the end of 2008
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units and would not make it obvious to respondents at which point a state becomes
worse than dead.
In summary, the literature review identified five TTO protocols for SWD of note.
Two of these – the MVH and Torrance designs – are widely used but, as discussed
earlier, give rise to problems because of their use of different valuation procedures for
SBD and SWD. Of the three further protocols identified, that used by Detsky et al.
(1986) which relies on a chaining method, and Stalmeier et al. (2007), which is not a
TTO, both overcome the problem of separate elicitation procedures for SBD and
SWD, but are each associated with other problems.  The method adopted by Robinson
and Spencer (2006) appears promising as a way potentially to overcome the problems
with existing protocols.
In order to assess this method further, and to consider whether there may be other,
related variants of the TTO that are theoretically possible but are not discussed or
tested in the literature, we developed a framework for systematically identifying the
component parts of any TTO and how these may feasibly be combined to create
alternative elicitation procedures. This is reported in the following section.
5. A framework for the systematic identification of all feasible TTO variants
The aim of this discussion paper is to identify the complete set of methodologies that
have been used in research to elicit values for SWD. However, we also wanted to
explore whether there exist other, theoretically possible TTO methodologies that had
not yet been discussed in the literature or empirically tested. To this end we set out to
identify, in general terms, the components of TTO methodologies and systematically
to investigate whether it would be possible to construct other, untried TTO
methodologies for the valuation of SWD using those components.
We were particularly interested to discover whether the approach of Robinson and
Spencer (2006), noted in the previous section, may have opened a door to a wider set
of other related, feasible TTO methodologies. As already noted, their approach
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operates by adding a ‘lead time’, spent in full health, to both of the scenarios in a
conventional TTO. This lead time enables trades to take place that would not
otherwise be feasible. Box 1 illustrates the lead time technique when used to value a
SBD. The area outlined by the dotted line in Box 1 comprises the ‘core’ states within
a conventional TTO. The area outlined by the dashed lines shows the addition of lead
times. In the case of SBD, trading into the lead time is not necessary. Box 2 shows the
valuation of a SWD. Some of the lead time in full health in the trading scenario is
‘given up’ to equalise the utility of this scenario with that of the alternative scenario -
effectively balancing out the negative utility associated with time spent in a SWD.
The Robinson and Spencer (2006) technique might be thought of as a form of
equivalent variation for a health loss to a SWD, in which a reduction of time in full
health produces the same decrement in utility as experiencing poor health. The
method was also suggested in a theoretical paper by Buckingham and Devlin (2006).
Depending on the precise manner in which the TTO question is framed, the
conventional TTO can be similarly regarded, but for poor states of health better than
being dead.
It is perhaps worth observing that the ‘conventional’ approach to TTO valuation of
SBD (i.e. the Torrance and MVH protocols outlined in the previous section) is not
feasible for SWD because the state of health being valued, if worse than dead, is
dominated by both of the two states (full health and dead) being used in the tradeoff.
No combination of time spent in full health and time dead can provide the same
negative utility as a SWD. The usefulness of lead times therefore lies in their ability to
alter the dominance between the ‘trading’ scenario (full health and dead) and the
‘alternative’ scenario, comprising time in the state to be valued. Adding a lead time in
full health to the conventional TTO means that the trading scenario no longer
inevitably dominates the alternative scenario. (It is perfectly feasible for full health
and being dead in the trading scenario to be dispreferred to full health and a SWD in
the alternative scenario, given sufficient lead time).
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Box 1. The lead time TTO for a state that happens to be better than dead.
lead full dead
Trading
Scenario
(full poor health
Alternative
Scenario
lead time
(full
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Box 2. The lead time TTO for a state that happens to be worse than dead
Given that lead times represent one possibility, symmetry suggests that lag times are
also possible - comparable additions of times available for trading, but added at the
end of the scenarios rather than at the start. An example of such an approach is
illustrated in Box 3.
Box 3. A lag time TTO for a state that happens to be better than dead
dead
Trading
Sceanrio
Alternative
Scenario
poor health
(full
(full
lag time
(full health)
poor health
Trading
Scenario
Alternative
Scenario
lag time
(full health)
dead full health
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We do not consider the multiple additional possibilities that ‘chaining’ (in which
valuations of one state are used in the valuation of other states) might offer. Such
chainings might be applied to any valuation methodology and provide further
possibilities in the valuation of states worse than dead. The TTO methodologies that
we do consider have the following general components:
1. The use of three ‘health’ states, namely: being in full health (or some
equivalent); being dead; and being in the health state to be valued (in our
context, the state that is valued as worse than being dead).
2. Two alternative scenarios of equal total duration, each being followed by dead,
in which the ‘trading scenario’ contains at least two component states whose
proportions within the fixed total duration are varied to equalise the utility of
the two alternatives.
3. The use of additional time common to both alternatives (lead or lag times), to
increase the amount of time subject to trading.
The intention in this section is to assess the viability of the various potential TTO
methodologies that might be constructed from combinations of these characteristics.
Viability is considered in the light of the criteria described below.
Most importantly, it is essential that trading between time spent in the various health
states within the trading scenario is capable of achieving the same utility as the
alternative scenario. If the states within the trading scenario are both superior to (i.e.
dominate) the state(s) in the alternative scenario (or vice versa) no equilibrium can be
achieved; and the potential methodology would be ‘non-feasible’.
In addition to the question of feasibility, other matters influence the viability of
potential methods. Incorporating all three health states (the anchor states of full health
and dead, as well as the state being valued) in the trading scenario can be shown to be
unhelpful. This possibility arises when lead times or lag times are used and when the
lead or lag time differs from the core health states in the trading scenario to which it is
attached. For example if the lag time shown in Box 3 were spent in poor health rather
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than in full health, the trading scenario would comprise the two ‘core states’ (time
spent in full health, time spent dead) as well as time spent in poor health. It follows
that the alternative scenario would now contain poor health plus more time spent in
poor health. This lag time would be redundant; it would not alter the existence or
otherwise of dominance between the scenarios. Redundancy can occur in other
circumstances where, under normal preference structures (good health preferred to
both being dead and bad health) equilibria would be achieved without trading into
lead or lag times.
There are three further considerations. Firstly, it is advantageous if the same method
is generalisable for use in the valuation of both SWD and SBD as, if different
methods were used within a study, the valuations might be incommensurable.
Secondly, it is potentially disadvantageous if the method confounds duration and
health state. This may be the case if equilibrium is achieved by varying the duration of
time spent in the health state being valued. Thirdly, it is also disadvantageous if the
method relies on the assumption of a ‘Lazarus effect’ in which living states follow
dead states. To be even remotely realistic, we would have to provide a believable
temporary alternative to being dead, such as a coma (however, this may not have the
same value as dead – Dolan 1997).
The full set of variants that we consider is shown in the cells of Table 4. We consider
whether feasibility, redundancy, generalisability, confounding, or Lazarus effects
apply to the combinations described by these cells.
Cell A1. This variant is used in the MVH valuation of SWD. The method is feasible
for SWD, but is not generalisable to SBD. It does not require a Lazarus effect,
however confounding exists which may be a problem.
Cell A2. This variant is used in the MVH valuation for SBD. It is feasible, does not
result in confounding, does not give rise to temporal inconsistency, however it is not
feasible for SWD.
Cell A3. This variant is not feasible for any state of health as full health dominates
any combination of poor health and dead.
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Cell B1. This variant has several problems. It is feasible for SWD, however the lead
time contributes nothing, it is not generalisable to SBD, it confounds duration with the
value of the health states, and it would rely on a Lazarus effect.
Cell B2. This combination is not feasible for SWD. No combination of being in poor
health and dead could render the trading scenario equivalent to full health and dead in
the alternative scenario.
Cell B3. This combination is not feasible. No combination of being in full health and
dead could render the trading scenario equivalent to poor health and dead in the
alternative scenario.
Cell C1. This combination is feasible. The trading scenario contains both full health
and poor health. Increasing the time in full health can be used to equalise the utility of
the trading scenario and the alternative scenario. However, the technique is
unsatisfactory in that the time spent in the state of health being valued is not fixed.
Cell C2. This combination is not feasible as no combination of full health, dead and
poor health can equal poor health worse than dead. Furthermore, the addition of poor
health to an alternative scenario that already contains poor health renders the lead
time redundant.
Cell C3. This combination is feasible (with a shorter time in poor health balancing the
combination of time in poor health and time in full health), however, it cannot be
generalised to SBD where the alternative scenario would dominate. Moreover,
confounding would occur.
Cell D1. This combination is feasible, however confounding could be a problem.
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Table 4. Full set of possible TTO Variants
States in the trading scenario
full and poor full and dead poor and dead
1 2 3
Neither lead
time nor lag
time
A
Feasible, not
generalisable, suffers
from confounding.
This technique was
used by the MVH
group for SWD
Not feasible for
SWD. No other
disadvantages. This
technique was used
by the MVH group
for SBD
Not feasible
Lead time =
being dead
B
Feasible, suffers from
redundancy,
confounding and a
Lazarus effect, not
generalisable
Not feasible Not feasible
Lead time =
poor health C
Feasible, suffers from
confounding Not feasible
Feasible, not
generalisable,
suffers from
confounding
Lead time =
full health D
Feasible, suffers from
confounding
Feasible, without
redundancy, is
generalisable, no
confounding, no
Lazarus effect. This
is the method
suggested by
Robinson and
Spencer (2006)
Not feasible
Lag time =
being dead E
Feasible, not
generalisable, suffers
from confounding
and redundancy
Not feasible Not feasible
Lag time =
poor health F
Feasible, but suffers
from redundancy and
a Lazarus effect
Not feasible
Feasible, but
not
generalisable
and suffers
from a Lazarus
effect
Lag time =
full health G
Feasible, but suffers
from redundancy, is
not generalisable, and
suffers from a
Lazarus effect
Feasible, without
redundancy, it is
generalisable, no
confounding,
suffers from a
Lazarus effect
Not feasible
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Cell D2. This is the method suggested by Robinson and Spencer (2006). It is feasible,
does not suffer from redundancy, is generalisable to SBD, does not give rise to
confounding, and does not rely on a Lazarus effect.
Cell D3. This combination is not feasible. The alternative scenario of full health for
the full duration, dominates the trading scenario. Furthermore, there is redundancy.
Cell E1. This combination is feasible but not generalisable to SBD. Confounding
could be a problem and the lag time is redundant.
Cell E2. This combination is not feasible. The trading scenario dominates the
alternative scenario.
Cell E3. This combination is not feasible. The alternative scenario dominates the
trading scenario.
Cell F1. This combination is feasible but no trading would take place into the lag time
for SWD. Furthermore, it relies on a Lazarus effect.
Cell F2. This combination is not feasible as the trading scenario dominates the
alternative scenario.
Cell F3. This combination is feasible, but would have to rely on a Lazarus effect.
Moreover it could not be generalised to SBD (in such cases the alternative scenario
would dominate the trading scenario).
Cell G1. This combination is feasible, but, for SWD, no trading would take place into
the lag time, while for SBD the trading scenario would dominate. Moreover, the
technique would require a Lazarus effect.
Cell G2. This combination is feasible. In fact it is the lag equivalent to Robinson and
Spencer’s technique, with similar advantages but with the exception that it would
require a Lazarus effect.
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Cell G3. Again this combination is not feasible as the alternative scenario dominates
the trading scenario. Moreover, the lag time is redundant.
After the completion of our literature search, our attention was drawn to an
unpublished Univesity of Utrecht PhD thesis by Verschuuren (2006), supervised by
Professors Ben van Hout and Gouke Bonsel. The thesis reports a TTO method,
employed in the valuation of episodes of pain, which might be thought of as a
combination of lead and lag times. A lead time in good health is added to the trading
scenario of good health (followed by dead), while a lag time in good health is added
after the time spent in poor health in the alternative scenario (followed by dead). The
method is similar to that of Robinson and Spencer (2006) except for the temporal re-
positioning of time spent in poor health in the alternative scenario. If we assume away
problems of time preference (the usual assumption in relation to the construction of
TTO valuations) and framing effects, the valuations should be the same as for the
Robinson and Spencer (2006) approach.
In fact, any sub-variant in which the health states take different temporal positions
between the trading and alternative scenarios will have similar feasibility properties as
the variants in which additional time is added in the same position in the trading and
alternative scenarios, with the exception of time preference and framing effects. Most
importantly, if dominance exists between the trading and alternative scenarios,
altering the position of the added time will not alter that dominance. In variants F1
and G1, temporal re-positioning can overcome Lazarus effects, however as we
observe in Table 4, these variants do have other serious problems associated with
them.
If we were to extend our validity criteria to incorporate the impact of time preference
on valuations, then sub-variants in which the temporal positioning of the added time is
altered seem unlikely to be helpful. When added time is in the same temporal position
in both the trading and alternative scenarios, the impact of time preference is likely to
be less than when the added time is in different temporal positions within the
scenarios.
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6. Conclusions from the application of a systematic framework
Breaking TTO into its component parts and considering alternative ways these might
be combined provides a way of categorising existing approaches, as well as
identifying remaining possibilities and their feasibility. Robinson and Spencer (2006)
is one of a wider class of lead time and counterpart lag time approaches, although in
terms of the criteria of feasibility, validity, redundancy and the avoidance of
implausibility (full health following death), none of these alternatives are obviously
superior to it. Further, it remains superior a priori to the class of non-lead time (and
non-lag time) approaches, including MVH and Torrance, on the grounds of its
employing a uniform elicitation procedure for SBD and SWD.
7. Conclusions
The way in which valuations of SWD are elicited is crucial – it affects not just the
valuations for states which, on mean values, are deemed worse than dead (< 0) but
also potentially affects the mean values of all states including those which, in
valuation ‘tariffs’, are better than dead (> 0). This in turn means that the way SWD
are valued will have important implications for the estimation of QALYs in economic
evaluation. Despite this, and non-trivial problems associated with widely used
methods for eliciting TTO values for these states, little attention has been given to
these issues in the literature.
Our review of the literature reveals that relatively few TTO studies incorporate
protocols for dealing with SWD – and still fewer are explicit about the way valuations
for these states have been handled. However, in large part this is related to the
predominance of TTO studies examining patients’ valuation of their own health
where, for a variety of reasons, SWD may be less evident. In valuation studies where
members of the general public have been asked to value health states which are
hypothetical to them – for example, to facilitate the estimation of the social value sets
widely used in economic evaluation – the protocols for valuation of SWD tend to be
more clearly described. However, nearly all such studies employ either the Torrance
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or MVH procedures – both of which rely on different elicitation procedures for SBD
and SWD, with all the attendant problems noted in the Introduction.
Out review of the empirical literature identified one study, Robinson and Spencer
(2006), which introduced a lead time in full health into both the ‘trading’ and
‘alternative’ scenarios, allowing a uniform TTO elicitation procedure to be used for
both SWD and SBD. Further investigation of the components of the TTO, using a
framework for systematically analysing all feasible variants thereof, suggests that
Robinson and Spencer’s lead time approach is one of a wider class of approaches that
might employ either lead times or lag times in the TTO scenarios. Further, the
temporal positioning of the lead/lag times might also vary between the scenarios being
compared.
We conclude that alternative protocols exist that can, a priori, overcome the problems
with current (Torrance and MVH) approaches to the TTO valuation of SWD. Further
research is required to design, test and compare the properties of the valuation data
generated by these alternative approaches.
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